The Federal Trade Commission investigation of pharmaceutical benefit managers

IF 3.7 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal Pub Date : 2024-11-24 DOI:10.1016/j.ahj.2024.11.009

Dina Sheira BA , Kevin Schulman MD

引用次数: 0

Abstract

The role of Pharmaceutical Business Managers remains a mystery to most physicians, and to most policy makers. Many of the business practices of a Pharmaceutical Business Manager are confidential and are beyond the purview of researchers. A recent Federal Trade Commission report raises many important questions about the role of these entities in the market. We review what the Federal Trade Commission found during their investigation and why physicians should be concerned.

查看原文本刊更多论文

联邦贸易委员会对药品福利管理公司的调查。

对于大多数医生和政策制定者来说，药品业务经理的角色仍然是个谜。药品业务经理的许多商业行为都是保密的，不属于政策研究人员的研究范围。联邦贸易委员会最近的一份报告对这些实体在市场中的作用提出了许多重要问题。我们回顾了联邦贸易委员会在调查中发现的问题，以及医生应该关注的原因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American heart journal 医学-心血管系统

CiteScore

8.20

自引率

2.10%

发文量

214

审稿时长

38 days

期刊介绍： The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.